Intuitive Surgical has secured 510(k) clearance from the FDA for its da Vinci 5 robotic platform in select cardiac procedures, including mitral valve repair and coronary artery bypass grafting. The clearance follows a multi-center clinical trial involving 120 patients across five U.S. hospitals, which demonstrated a 25% reduction in operative time and a 40% decrease in length of hospital stay compared with conventional minimally invasive approaches. This expansion into cardiac applications could drive additional system placements, building on the company’s existing installed base of over 11,100 da Vinci systems globally.

Intuitive Surgical has received FDA approval for an artificial intelligence module on its Ion endoluminal system, marking the second significant AI milestone in six months. The new software uses machine-learning algorithms trained on more than 50,000 procedures to automate lesion targeting and improve biopsy accuracy by up to 15%. Management reports an 18% year-over-year increase in total procedures performed on da Vinci systems, underscoring the growing data set that fuels future autonomous capabilities. Despite a current price-to-earnings multiple of 66, the company’s ongoing AI investments and recurring service revenue of $1.6 billion in the latest fiscal year support a premium valuation for investors focused on long-term innovation.

In Greater China, system placements rose just 5% in the past year, down from 12% growth in the prior period, as government tenders favor domestic manufacturers offering lower upfront costs. Surveys of 200 cardiothoracic surgeons indicate a 70% preference for da Vinci’s user interface and ergonomics, but pricing concessions of up to 20% have been required to secure new contracts. Intuitive Surgical’s management has flagged the potential entry of two local robotic platforms in 2026, prompting plans to increase investment in regional training programs and service centers to reinforce its clinical support advantage.